The Nuanced Implications for Pharma Importers of the Trump Tariff Rejection by the Supreme Court

The Supreme Court’s 6–3 ruling striking down tariffs imposed under the International Emergency Economic Powers Act (IEEPA) marks a significant development for pharmaceutical development and manufacturing professionals who oversee global supply chains.¹ Chief Justice John Roberts noted that “the president asserts the extraordinary power to unilaterally impose tariffs of unlimited amount, duration and scope,” yet the administration cited no statute demonstrating that Congress granted such sweeping authority under the 1977 law.¹ Although the decision nullifies broad reciprocal tariffs—including the 34% duty on goods from China—its implications for the pharmaceutical industry are more complex, as different statutory authorities continue to govern sector-specific trade measures.²

Why Does the Distinction Between Legal Authorities Matter for Drug Manufacturing?

It is critical for industry leaders to recognize that most high-profile pharmaceutical tariffs discussed in 2025 were intended to be imposed under Section 232 of the Trade Expansion Act, rather than the International Emergency Economic Powers Act, often referred to as IEEPA.² In spring 2025, the Department of Commerce launched a Section 232 investigation into pharmaceutical imports and ingredients to assess potential national-security risks. President Trump subsequently announced plans for a 100% tariff on branded or patented pharmaceutical products specifically linked to that investigation.

Consequently, the Supreme Court's ruling against IEEPA primarily affects mega-tariffs and global reciprocal actions, while pharmaceutical-specific measures grounded in national-security authority remain potentially in force.² For example, Section 232 tariffs on steel and aluminum are separate and remain in place even after this decision. Furthermore, negotiated exceptions and trade agreements with the UK and EU were designed to shape how Section 232 duties on drugs would be applied, distinct from the broader emergency powers recently curtailed. This means that while some broad import taxes are gone, the targeted investigations into the pharmaceutical supply chain have not been directly invalidated.

How Have the Tariffs Been Affecting the Pharma Industry?

On the tariff developments, Kristin Ciriello Pothier, Americas Life Sciences Leader, KPMG, comments, "Today's ruling and subsequent developments are only part of the story for the life sciences industry, leaving key questions around tariff exposure and trade uncertainties. Now is the time to pressure-test sourcing models and accelerate AI-driven forecasting. Resilience and disciplined scenario planning will be essential as trade dynamics continue to shift."

The tariffs have caused the industry pivot toward domestic manufacturing, which has accelerated global trade tensions.³ Major developers have already committed billions to reshoring to mitigate potential duties and ensure supply chain resilience. For example, Eli Lilly and Company initiated plans for four new manufacturing sites, bringing its total US capital commitments to over $50 billion.⁴ More recently, Johnson & Johnson announced a $1 billion investment in a Pennsylvania manufacturing site.⁵

What Are the Long-Term Operational Implications of Shifting Trade Policies?

This massive reallocation of capital responds to an invest-or-tariff ultimatum, where high taxes could be avoided by beginning US facility construction.³ This is a vital shift, as 90% of biotech firms rely on imported components for at least half of their approved products. High costs have already squeezed profit margins, forcing some companies to delay R&D. While the court decision limits broad emergency taxes, onshoring continues to provide benefits like improved quality control and reduced miscommunication. Manufacturers are now prioritizing trade compliance and supplier diversification to balance domestic capacity with flexibility. The industry continues to advocate for stable policies to protect critical inputs like APIs and excipients. By investing in domestic R&D and localized APIs, firms aim to strengthen medicine supply security for the future.

References

1. ​Supreme Court strikes down most of Trump’s tariffs in a major blow to the president. NBC News. Published February 20, 2026. Accessed February 20, 2026. https://www.nbcnews.com/politics/supreme-court/supreme-court-strikes-trumps-tariffs-major-blow-president-rcna244827
2. Sagonowsky E. Supreme Court steps in as Trump’s tariffs are thrown out. FiercePharma. Published February 20, 2026. Accessed February 20, 2026. https://www.fiercepharma.com/pharma/supreme-court-steps-trumps-tariffs-thrown-out
3. Cole C. The year of the tariff: pharmaceutical supply chain reimagined in 2025. Pharmaceutical Technology. Published Year. Accessed February 20, 2026. https://www.pharmtech.com/view/the-year-of-the-tariff-pharmaceutical-supply-chain-reimagined-in-2025
4. Cole C. Lilly invests $3.5B in Pennsylvania injectable medicine facility. Pharmaceutical Technology. Published February 13, 2025. Accessed February 20, 2026. https://www.pharmtech.com/view/lilly-invests-35b-in-pennsylvania-injectable-medicine-facility
5. Zubulake Z. Johnson & Johnson Announces $1B Investment in Pennsylvania Manufacturing Site. Pharmaceutical Technology. Published February 19, 2026. Accessed February 20, 2026. https://www.pharmtech.com/view/johnson-johnson-announces-1b-investment-in-pennsylvania-manufacturing-site